Estrogen Receptor Homeostasis

NIH RePORTER · NIH · R01 · $393,956 · view on reporter.nih.gov ↗

Abstract

Abstract Estrogen receptor alpha (ERα) acts to integrate systemic signals from estrogens and growth factors to control numerous aspects of development and homeostasis within the organism. In response to acute exposure to ligand binding ERα is degraded via the 26S proteasome pathway. However, in order for continued estrogen responsiveness to be maintained during the reproductive, premenopausal stage mechanisms must exist to regulate steady state protein levels of ERα. Little is known about the regulation of ERα steady state levels. Unexpectedly, using multiple approaches including various mouse models and mammary gland transplants we have identified a novel mechanism in which physical association of the Ser/Thr protein kinase, RSK2, with ERα regulates the steady state protein levels of ERα in the adult mammary gland. Furthermore, the ability of RSK2 to regulate ERα levels was not confined to the mammary gland as we observed decreased ERα levels in the uteri and liver of adult female mice in which RSK2 was knocked out. We hypothesize that the RSK2/ ERα complex regulates the steady state protein levels of ERα in vivo to maintain estrogen-responsiveness in the adult. To further investigate our hypothesis we will focus on the mammary gland because mammary gland regeneration experiments in combination with altering gene expression greatly facilitates mechanistic studies. We propose to test our overall hypothesis through these Aims. In Aim 1 we will identify the mechanism by which RSK2 stabilizes ERα protein levels in vivo. In Aim 2 we will identify how the RSK2 contributes to estrogen responsiveness in vivo. Data generated in this proposal will be analyzed using the appropriate statistics for end point and longitudinal analysis. The outcome of these experiments will increase our understanding of the mechanisms that regulate the functions of ERα in normal homeostasis and will provide insight into disruption of this process that can result in estrogen-dependent cancers and metabolic dysfunction.

Key facts

NIH application ID
10164759
Project number
5R01DK113423-04
Recipient
VANDERBILT UNIVERSITY MEDICAL CENTER
Principal Investigator
Deborah Lannigan
Activity code
R01
Funding institute
NIH
Fiscal year
2022
Award amount
$393,956
Award type
5
Project period
2018-06-01 → 2025-05-31